Your session is about to expire
← Back to Search
Lacutamab for Peripheral T-Cell Lymphoma
Study Summary
This trial is testing a new single drug to treat a specific type of relapse lymphoma in people who express a certain protein. They want to see if it's safe and works well.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had more than 8 different treatments for my condition, not counting stem cell transplants.I can take care of myself but might not be able to do heavy physical work.I have a type of peripheral T-cell lymphoma.I have not taken any cancer treatment drugs for at least 3 weeks.I have mostly recovered from side effects of my previous cancer treatment.I can take care of myself but might not be able to do heavy physical work.I agree to use birth control during and for 9 months after the study.I have been treated with lacutamab before.My cancer has not responded to or has worsened after treatment, and I've completed at least 2 cycles of a previous therapy.My kidneys are functioning well enough for treatment.I have not had major surgery in the last 4 weeks.I do not have any serious health issues that would stop me from following the study's treatment plan.I do not have dementia or any condition that affects my ability to understand and agree to the study.I have not taken any cancer treatment drugs for at least 3 weeks.I have not received any live vaccines in the last 4 weeks.My cancer has spread to my brain or spinal cord.My disease has not improved or has worsened despite treatment, and I've completed at least 2 cycles of a previous therapy.My test shows KIR3DL2 expression in my biopsy.I do not have a severe infection right now.I haven't had cancer in the last 3 years, except for certain types like skin cancer or thyroid cancer.I have undergone at least one round of systemic therapy.I am not currently receiving any cancer treatments like chemotherapy or immunotherapy.I have an active Hepatitis B or C infection confirmed by a PCR test.I had a stem cell transplant using my own cells less than 3 months ago.I have severe heart failure.I have had a transplant from another person.My kidney function, measured by creatinine, is within normal limits.I have recovered from serious side effects of my previous treatments, except for hair loss, nerve issues, or hormone problems that are under control.I have undergone at least one round of systemic therapy.I am a woman who can become pregnant and have had a period in the last year. My pregnancy test before treatment was negative.I am 18 years old or older.My test shows at least 1% KIR3DL2 expression in my lymph node biopsy.I am 18 years old or older.My kidneys are working well enough, based on a specific test.My liver enzymes are within normal limits.I have a type of cancer known as peripheral T-cell lymphoma.
- Group 1: PTCL that express KIR3DL2
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the clinical trial running in North America being conducted at multiple locations?
"There are 11 medical sites offering this clinical trial, such as Goshen Health-Goshen Hospital in Goshen and Allegheny Health in Pittsburgh. Additionally, the University of California at Irvine - Chao Family Comprehensive Cancer Center is participating in Orange, along with 8 other centres."
How many individuals are being enrolled in this medical experiment?
"To facilitate the completion of this medical trial, 40 qualified patients are required. Potential participants can sign up at either Goshen Health-Goshen Hospital in Indiana or Allegheny Health in Pittsburgh, Pennsylvania."
Has lacutamab received the regulatory go-ahead from the Food and Drug Administration?
"Lacutamab's safety was cautiously evaluated and given a score of 1 as this clinical study is only in its first phase, with limited data available to assess efficacy."
Are there still vacancies available in this experiment for participants?
"According to clinicaltrials.gov, this trial is presently recruiting patients. It was initially made available on March 17th 2022 and the details were most recently updated on April 4th 2022."
Share this study with friends
Copy Link
Messenger